Brief: Pharmather Holdings Submits FDA Meeting Package To Discuss Phase 3 Program And Fast Track Designation For Ketarx™ (Ketamine) In Parkinson’S Disease
01/02/2023 16:36
Feb 1 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER HOLDINGS SUBMITS FDA MEETING PACKAGE TO DISCUSS
PHASE
3 PROGRAM AND FAST TRACK DESIGNATION FOR KETARX™ (KETAMINE) IN
PARKINSON’S DISEASE
* PHARMATHER HOLDINGS LTD - GOAL DATE FOR FDA IN PROVIDING
ITS
WRITTEN RESPONSES IS MARCH 20, 2023
Source text for Eikon: ID:nGNX22B8c1
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application